

Index

- abdominal radical hysterectomy (ARH) 222, 238
- abdominal radiotherapy 420
- abdominal surgery 596, 600, 602, 783
- major 597, 600
- upper 287
- abnormalities, metabolic 742–43, 750–51
- acetic acid 104, 109–10, 174–75, 186
- actinomycin 94, 442, 451, 453, 492–94, 496–98, 664, 668, 672
- adenocarcinoma 28, 44, 48, 83–85, 107–8, 144–45, 173, 204, 206, 244, 269, 343, 367, 566, 717
- clear cell 85, 205–6, 343, 369
- endometrioid 206, 267, 269, 272, 299–300, 329, 343
- invasive 191–92
- recurrent 246
- adenosarcoma 316, 318, 327–28
- adjuvant chemotherapy 297, 301, 322, 333, 378, 382–84, 386, 390–91, 420, 444, 446, 449–50, 460, 527
- adjuvant pelvic irradiation 54, 331–32
- adjuvant pelvic radiotherapy 322, 331
- adjvant radiotherapy 219–21, 290, 292–93, 296, 303, 322, 328, 331, 524, 529, 643
- postoperative 59, 218, 322
- adjuvant treatment 59, 68, 71, 220, 246, 292–93, 326–27, 331, 420, 460, 517, 528–29, 546, 712–13, 778
- adnexal masses 361, 372, 375, 549, 777
- AGC *see* atypical glandular cells
- alkylating agents 424, 544, 664, 667–68, 673, 689–91, 722, 725
- alpha-fetoprotein 562–63
- anaemia 395, 406, 481, 596, 681, 693–94, 728
- anal cancer 135, 141, 143, 149, 159
- anastomosis, end-to-end 626–28, 732
- anastrozole 423, 517, 528, 716
- angiogenesis 18, 26, 414, 416, 695–96, 700
- anogenital cancers, non-cervical 133, 143
- anthracycline-based chemotherapy 691–92
- anthracyclines 530, 669, 689, 722
- anti-cancer drugs 678, 696, 698–700
- anti-neoplastic agents 663
- anti-neoplastic drugs 660, 663, 665, 682
- anti-tumour antibiotics 544, 668–69
- antibodies 142, 147, 150, 153–54, 161, 165, 423, 441, 483, 709
- anticancer drugs 411, 413, 520
- antigens 30, 132, 150, 375, 556–57, 704–6, 709–10
- tumour-associated 565, 704–5
- anus 36, 39, 45, 49, 51–52, 134, 136, 619, 621

- apoptosis 2, 16, 21, 23, 26–27, 191, 203, 418, 670, 695, 698
aromatase inhibitors 326, 423, 517, 528, 532, 713, 715–16
ASC *see* atypical squamous cells
ascites 342, 362, 372, 374, 378, 383, 422, 439, 464, 561, 564, 595, 743, 765–67
ascitic fluid 375, 563, 766, 768
atypical glandular cells (AGC) 108, 173, 191, 734
atypical hyperplasia 267, 272–73, 275, 279, 284–85, 509, 714
atypical squamous cells (ASC) 108, 112, 136, 173
- Bartholin's glands 36–38, 48, 618–20
Batholin's gland carcinoma 69
BCRP *see* breast cancer-resistant protein
BCS *see* breast-conserving surgery
benign tumour 320, 366, 370, 463–65, 470, 488, 587
bevacizumab 242, 304, 392–93, 397, 399, 415, 418, 449, 461, 530, 682, 700
biologic response modifiers (BRMs) 687–88, 690, 692, 694, 696–98, 700
biomarkers 32, 376, 410, 560, 562, 564
biopsy 41, 45–46, 49, 58, 152, 172–73, 179, 190–91, 199, 209–10, 229, 302, 451, 514–15, 521
bivalent HPV vaccine 147, 149, 153–58, 162
bivalent vaccine 146–47, 154, 157
bladder 3, 5–6, 51, 209, 225, 573–74, 583, 610, 612, 614–15, 617–18, 628–29, 645–46, 730–32, 768–70
bladder cancer 4, 647, 694
bladder dysfunction 226, 732–33, 768
bladder injury 629, 732
bladder radiation injuries 730–31
bleomycin 442, 450–54, 460, 495, 498, 664, 669, 682, 723, 764–65
borderline tumours 28, 356, 366, 368–69, 375, 380–82, 557, 582
bowel, small 404, 573, 625–26, 645, 727, 729, 744
Bowen's disease 43–44
brachytherapy 60, 91, 230, 232–33, 245, 289–90, 293–98, 302, 639, 642–44, 653–54
high-dose-rate 643–44
intravaginal 94, 295
brain tumour 651, 727
BRCA mutations 353, 355–56, 358, 515
breast cancer 5–7, 25, 271, 359, 413–14, 505–15, 517–25, 527–29, 531–32, 540–41, 543, 545–46, 638–39, 701, 711–13
advanced 529–30, 689, 712
assessment of 522
deaths 505, 509, 512
diagnosis 519
early 512, 525–26, 546
early-stage 528
hormonal therapy 527
incidence 7, 546
invasive 505, 508, 518, 531–32, 711
male 355, 359, 511
metastatic 527, 529–30, 669
mortality 512
non-invasive 517, 532
preventing recurrence 713
prevention of 531
recurrence 509, 711

- recurrent 531
- screening 512–13
- survival 519
- treatment 523
- breast cancer-resistant protein (BCRP) 666
- breast-conserving surgery (BCS) 517–18, 524–25, 530
- breast-ovarian cancer, hereditary 354–55
- breast-ovarian cancer syndrome 28
 - hereditary 355, 359
- breast-preserving surgery 519, 546
- breast self-examination (BSE) 512
- breast surgery, reconstructive 525, 530
- breast tissue 273, 524, 526, 528, 715
- Brenner tumour 366–67, 369, 562
 - malignant 370
- BRMs *see* biologic response modifiers
- BSE *see* breast self-examination

- cancer
 - advanced 117, 693, 728
 - detection of 30, 32, 365
 - direct metastasis of 40, 622
 - female 7, 135
 - high-grade non-invasive 525
 - hormone-receptor-positive 509, 712
 - non-cervical 135
 - virus-induced 24, 706
- cancer biology 402, 704
- cancer cachexia 750–51
- cancer carcinogenesis 2
- cancer cases, invasive cervical 204
- cancer cell death 413, 529
- cancer cells 2, 18, 26, 139, 371, 398, 414, 416, 418–19, 425, 529, 660, 666, 690, 704–6
 - proliferation of 563, 699
 - trastuzumab-resistant 530
- cancer management 540, 545, 660
- cancer risk 4, 10, 509
- cancer stem cells 17
- capsid proteins 130, 145–46, 164
- carboplatin 241, 298–99, 301, 332–33, 384, 388–91, 393, 405–7, 412, 415, 544, 668, 678, 682–83, 690–91
- carboplatin-paclitaxel regimen 392, 395, 418
- carcinoembryonic antigen 69, 549, 562, 566, 704
- carcinogenesis 2, 13–18, 20, 22–24, 26, 28–30, 32, 357
- carcinoma 49, 56, 69, 83, 89, 133, 136, 206, 210–12, 268–69, 274, 316, 318–19, 329, 340
 - concurrent 284
 - ductal 509, 517–18, 532
 - endometrioid 329, 444, 458
 - invasive 84, 86–87, 138, 172, 176, 204, 207, 382
 - lobular 509, 515, 517–18
 - small-cell 68, 246
 - verrucous 67–68, 84, 90, 547
- carcinoma of endometrium 263–64, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, 288, 290, 551
- carcinoma of ovary 422, 581, 716
 - small cell 370–71
- carcinoma of vagina 81–84, 86, 88, 90, 92, 94, 717
- carcinosarcoma 271, 273, 316–19, 322, 324, 327–31, 366–67
- CBE *see* clinical breast examination
- CCA *see* clear cell adenocarcinoma
- cervical cancer
 - advanced 117, 208, 220, 234, 236–38, 241, 651, 779
 - aetiology of 200
 - early-stage 213, 215, 217, 221–22, 247, 565, 779

- fertility-preserving surgery 228
 invasive 100
 management of 206, 213–14,
 238
 markers 567
 radical hysterectomy 222–23,
 225
 recurrent 239, 241, 247–48, 576,
 578, 586
 screening 97–98, 100, 102, 104,
 106, 108, 110, 112, 114, 116,
 118, 120, 122
 survival rate 213
 tumour markers 565
 invasive 99, 121, 139, 172, 189,
 201, 204–6, 228
 cervical intraepithelial neoplasm,
 management of 179, 181
 cervical lesions, pre-malignant 107
 chemotherapy
 combination 406, 443, 463, 493,
 497, 679, 727
 combined 298, 323, 495–96, 698
 first line 323, 391–92, 407, 409,
 411, 421, 424
 multi-agent 492–94
 neoadjuvant 62, 219, 228, 230,
 238, 242–45, 290, 387,
 399–402, 527, 530, 547, 549,
 676, 778
 platinum-based 239, 402, 417,
 453, 460
 postoperative 290, 496
 pre-operative 94
 second line 390, 403, 406,
 408–9, 411, 452–53, 493
 side effects 722–23, 725
 single agent 493, 727
 systemic 94, 676
 cisplatin 92–93, 235–37, 239–41,
 243–44, 246, 297, 323–24,
 388–91, 396–97, 442,
 450–53, 495–96, 667–68,
 689–91, 723–25
 side effects of 724
 cisplatin-based chemotherapy
 329, 446
 sequential 421
 cisplatin monotherapy 239–40
 cisplatinum 383, 391, 673, 682
 clear cell adenocarcinoma (CCA)
 85, 90, 93, 205–6, 343, 369
 clear cell adenocarcinoma of
 vagina 93
 clear cell carcinoma 85, 267–69,
 287, 298, 302, 369, 383, 444
 clear cell tumours 369, 378
 clinical breast examination (CBE)
 512–14
 colon cancer 694, 698
 colony stimulating factors (CSFs)
 490, 693–94, 726
 colorectal cancer 5, 415, 688, 692,
 696, 708
 colorectal surgery 604
 elective 604
 colposcopic examination 46, 87,
 120, 175–76, 190, 209
 colposcopy 110, 112–13, 115–17,
 119–20, 172–79, 181, 190,
 192, 576
 complete hydatidiform mole
 479–82, 484, 486–87, 489,
 580
 cryotherapy 42, 87, 110, 113, 180,
 182, 186–89, 199
 CSFs *see* colony stimulating factors
 cyclophosphamide 94, 345,
 384, 388–91, 442, 452–53,
 493–94, 496, 527, 529, 544,
 668–69, 673, 682–83, 690
 cysts, dermoid 366, 440, 444, 446
 cytokines 484, 680, 693, 695–98,
 707–8, 744–45
 cytologic atypia 273, 320
 cytologic screening 143–44
 cytologic test 113–15, 144
 cytological surveillance 179
 cytology
 conventional 104

- liquid-based 104–5, 115, 118
- cytoreduction, secondary 401, 404–5, 778
- cytoreductive surgery 378, 383–85, 398–99, 404, 452, 581
- optimal 402
- cytotoxic drugs 327, 395–96, 451, 453, 492, 544, 653, 666, 678, 690, 698, 722, 724, 752
- debulking surgery 290, 326, 379, 385, 402
- primary 396, 402
- deep vein thrombosis (DVT) 65–66, 208, 597–98
- dendritic cells 132, 693, 707, 709
- dexrazoxane 669, 689, 723
- DFS *see* disease-free survival
- diarrhoea 161, 295, 417, 420, 601, 700, 735, 747–49, 753
- disease-free interval 303, 325, 384, 403, 405, 463
- disease-free survival (DFS) 218, 220–21, 234–35, 237, 242, 244, 292, 294, 331, 524, 528
- docetaxel 323–24, 390–91, 394, 405, 409, 527, 671
- doxorubicin 93–94, 246, 299–300, 323–24, 327, 345, 388–89, 406, 409, 424, 527, 667–69, 682–83, 689, 723
- drug resistance 17, 409, 424, 492, 665–67, 698
- DVT *see* deep vein thrombosis
- dysgerminoma 366, 369, 438–42, 444, 449–53, 562, 641
- early-stage cervical cancer, treatment 215
- ectocervix 198–99
- EGFR *see* epidermal growth factor receptor
- EGLs *see* external genital lesions
- EIC *see* endometrial intraepithelial carcinoma
- EIN *see* endometrial intraepithelial neoplasia
- embryonal carcinoma 366, 439–40, 449, 563
- embryonal tissue 447
- embryonal tumour 450, 663
- endocervical glands 85, 190
- endodermal sinus tumour 84, 366, 438–40, 443, 450, 550, 562–63
- endometrial adenocarcinoma 273–74, 279, 713
- hormonal therapy 713
- endometrial biopsy 278, 460, 578
- endometrial cancer 29–30, 266–73, 275–82, 287–88, 290–92, 295–96, 298–300, 302–5, 551, 567, 579–80, 586, 712, 714–17, 776–77
- advanced 290, 297–98
- aggressive 713
- diagnosis of 280, 317
- early-stage 291–93, 567
- high-risk 298
- high-risk early-stage 295–97
- metastatic 299–300
- persistent 304–5
- prevention of 277
- recurrent 281, 295, 300, 304, 714–15
- tamoxifen-induced 712
- tumour markers 567
- endometrial carcinoma 269, 278, 286–87, 289, 291, 293, 295, 297–99, 318, 329, 375, 578–79, 713–14
- endometrioid 267, 274
- high-grade 329
- treatment 287, 289, 291, 293, 295, 297

- endometrial cells 108, 175, 713
 endometrial hyperplasia 271–74,
 277–78, 284–86, 460–61,
 464, 712, 714
 atypical 273–74, 284–85, 715
 endometrial intraepithelial
 carcinoma (EIC) 268, 276,
 300
 endometrial intraepithelial
 neoplasia (EIN) 268,
 274–76, 284
 endometrial lesions 279–80
 tamoxifen-induced 713
 endometrial neoplasia 713–14
 endometrial pathology 273–74,
 277, 280, 578, 712–13
 endometrial sampling, pipelle 279
 endometrial stromal sarcomas
 (ESS) 316, 318–19, 322,
 324–27, 329, 333, 715, 717
 endometrial tumour 579, 715
 endometrioid 295, 367, 378
 endometrioid cancer 378
 endometrioid type 29, 300,
 368–69
 endometriosis 216, 325, 357, 362,
 369, 557
 endometrium 72, 222, 263–70,
 272–80, 282–86, 288, 290,
 298–300, 302, 325, 356–57,
 369, 551, 574–75, 712–14
 enteral feeding 746–47, 751, 753
 enteral nutrition 745–48
 EOC *see* epithelial ovarian cancer
 epidermal growth factor receptor
 (EGFR) 26, 326, 394,
 414–17, 487, 506, 519,
 528, 530, 700–1
 epimutation 19
 epithelial cells 20, 45, 108, 132,
 138–39, 276, 362, 518, 692
 epithelial endometrial cancer
 302–3, 316
 epithelial ovarian cancer (EOC)
 349–56, 358, 360, 362–66,
 368–76, 378–80, 382,
 390–94, 400–2, 438–39,
 450–52, 549–50, 557,
 559–63, 717
 epithelial ovarian cancer, invasive
 382
 epithelial ovarian tumours 368,
 380
 epithelial tumours 365, 369, 698
 epithelial uterine cancer 266–67,
 269, 271
 epithelioid trophoblastic tumour
 (ETT) 476, 478, 486,
 488–89, 496
 epithelium 37, 44, 138–39, 143,
 172, 175, 190, 202, 210–12,
 344, 366, 379–80, 458, 620,
 623
 endocervical 177, 190, 368
 erlotinib 242, 394, 399, 417, 700
 ESS *see* endometrial stromal
 sarcomas
 etoposide 93, 246, 323, 442,
 450–51, 453–54, 493–96,
 498, 667, 671, 682, 722–23
 ETT *see* epithelioid trophoblastic
 tumour
 external beam radiotherapy 60,
 230, 289–90, 293, 295, 526,
 543, 638
 external genital lesions (EGLs)
 150, 152, 159
 extramammary Paget's disease
 42–43
- fallopian tube 265, 339–44, 346,
 359, 365, 392, 778
 fallopian tube cancer 339–46, 363,
 393–94, 415, 557
 diagnosis of 341
 primary 340, 342–43
 fallopian tube carcinoma 340–42,
 344–46, 402
 primary 340, 344–45
 familial cancer risk 30

- febrile neutropenia 693–94,
725–26, 734
- fertility-preserved surgery 228,
381
- fertility-sparing surgery 225
- FIGO staging of cervical cancer
210
- fine needle aspiration cytology
(FNAC) 56, 73, 210, 401,
516, 583
- fistula 397, 420, 575, 646, 727,
729–31
- uretero-vaginal 732
- FNAC** *see* fine needle aspiration
cytology
- foetus 158, 480, 540–45, 547,
642, 704
- folinic acid 497, 688
- follicle-regulatory protein (FRP)
462
- FRP** *see* follicle-regulatory protein
- gastric cancer 567, 694
- gastrointestinal radiation toxicity
728–29
- gastrointestinal stromal tumour
416–17
- gastrointestinal toxicity 237, 300,
672, 727–29
- GCT** *see* granulosa cell tumour
- gemcitabine 237, 240–41, 323–24,
391–92, 394–95, 405–6, 408,
415, 417, 460, 664, 669–70,
682
- gene therapy 31, 425
- genetic mutations 28, 510–11, 543
- genital infection 205
- genital warts 49, 140–41, 148–49,
151–52, 156, 159, 161
- germ cell tumours 343, 438, 441,
444, 448, 451–52, 472, 549,
674
- male 453–54
- malignant 439, 450
- non-seminomatous 448
- germ cells 19, 366, 458
- gestational trophoblastic disease
(GTD) 475–80, 482–86, 488,
490, 492, 494, 496, 498, 556,
580–81
- gestational trophoblastic neoplasia
486, 489
- gestational trophoblastic neoplasm
(GTN) 477, 484–85, 487–90,
492–93, 496–97, 563
- glutathione 424, 666, 689–90
- glutathione-S-transferase (GST)
412, 424
- granulosa cell tumour (GCT)
458–62, 471–72, 563, 717
- granulosa cells 458–59, 461, 646
- tumour 458–61, 471–72, 563
- granulosa-stromal cells tumour
458–59, 461
- growing teratoma syndrome (GTS)
448–49, 452
- GST** *see* glutathione-S-transferase
- GTD** *see* gestational trophoblastic
disease
- GTN** *see* gestational trophoblastic
neoplasm
- GTS** *see* growing teratoma
syndrome
- gynaecologic cancer, tumour
markers 555–56, 558, 560,
562, 564, 566, 568
- gynaecologic malignancies 27, 29,
350, 585, 615, 623, 776
- gynaecologic oncologist 281, 375,
401, 503–4, 506, 508, 510,
512, 514, 516, 518, 520, 522,
524, 526
- gynandroblastoma 367, 459,
468–69, 471
- HALS** *see* hand-assisted
laparoscopic surgery

- hand-assisted laparoscopic surgery (HALS) 778
- HBOC *see* hereditary breast-ovarian cancer
- HCG *see* human chorionic gonadotropin
- HEN *see* home enteral nutrition
- hepatocellular cancer 145, 694
- hereditary breast-ovarian cancer (HBOC) 354–55, 359–60
- HIPEC *see* hyperthermia intraperitoneal chemotherapy
- home enteral nutrition (HEN) 748–49
- hormonal therapy 300, 304, 325, 327–28, 403, 423, 517, 520, 527, 529, 703–4, 706, 708, 710, 714–16
- HPV
see human papilloma virus
- low risk 132, 137, 143, 201–2
- HPV genome 130–31, 140
- HPV in cervical cancer 204
- HPV infection in lower genital tracts 130–31, 133
- HPV-related vulvar cancer 49
- HPV vaccination 99, 129–30, 132, 134, 136, 138, 140, 142, 144–46, 148–50, 152, 154, 156, 158–60, 162
- HPV vaccines 30, 111, 136, 142, 145–46, 157–64
- human chorionic gonadotropin (HCG) 441, 449, 483–84, 486–88, 491, 563
- human epididymis protein 362, 561–62, 567
- human papilloma virus (HPV) 28–29, 41, 100–1, 111–21, 130–34, 136, 139–44, 146–51, 153–56, 161–65, 178–79, 191–92, 201–2, 204–5, 717
- hydatidiform mole 476–85, 487
- hydroxyurea 235, 494, 682
- hypercalcaemia 370–71, 462, 520, 522
- hyperplasia 29, 133, 271–73, 283, 714
- hyperthermia intraperitoneal chemotherapy (HIPEC) 398
- IAP *see* immunosuppressive acidic protein
- image-guided radiation therapy 651
- immunosuppressive acidic protein (IAP) 567
- immunotherapy 423, 704–5, 707–9
- active 708
- passive 708
- vaccine-based 707
- IMRT *see* intensity-modulated radiation therapy
- inhibin 362, 458, 461–63, 467, 549, 563–64
- intensity-modulated radiation therapy (IMRT) 233, 298, 650–51
- interval debulking surgery 400–2
- intra-operative radiation therapy (IORT) 652–53
- intraperitoneal chemotherapy 396–97
- intraperitoneal cisplatin 397
- IORT *see* intra-operative radiation therapy
- LABC *see* locally advanced breast cancer
- laparoscopy-assisted vaginal hysterectomy (LAVH) 776
- LAVH *see* laparoscopy-assisted vaginal hysterectomy
- LBC *see* liquid-based cytology

- LEEP *see* loop electrosurgical excision procedure
- leiomyosarcoma 71, 84, 94, 206, 316, 318–24, 332, 674
- diagnosis of 320
- low-grade 320–21
- lesions
- cancerous 135, 143, 146, 160, 162
 - endocervical 144, 182
 - lateralized 50, 55, 59
 - multifocal 46, 87–88
 - pre-cancerous 137, 159
 - pre-malignant 274
 - precursor 276–77, 300
 - premalignant 45, 274, 283–84
 - premalignant vulvar 41
- leukaemia 6, 19, 416, 420, 454, 493, 647, 660, 698, 701, 723
- lichen sclerosis 41–42, 47–48
- ligaments
- cardinal 198, 226, 611, 614, 617–18
 - round 39, 71, 264–66, 371, 610–11
 - transcervical 265, 611
 - uterosacral 198, 223, 225–26, 265, 611–12, 614, 618, 633
 - vesicouterine 224–26, 612, 618
- liposomal doxorubicin 390, 392, 399, 406, 409, 669, 672
- liquid-based cytology (LBC) 104–5, 115, 118
- liver 3, 5–6, 50, 208, 303, 318, 322, 377, 439, 452–53, 489–90, 494, 544, 562, 623
- liver cancers 4, 6, 18, 136
- locally advanced breast cancer (LABC) 529–30
- loop electrosurgical excision procedure (LEEP) 46, 113, 182–85, 189, 215
- low-risk gestational trophoblastic neoplasm, treatment 492–93
- Lugol's iodine 87, 109, 184
- lung 3, 5–6, 8, 50, 68, 93, 208, 248, 266, 303–4, 318, 322, 325, 371, 489–91
- lung cancers 5, 7, 136, 362, 566, 698
- small cell 394, 696
- lung metastases 489
- lymph node metastasis 213, 215, 217, 303, 330
- lymph nodes 50, 53, 58–60, 67, 73, 208, 213, 281, 287–90, 326, 343, 439, 519, 525–26, 583–85
- axillary 504, 524
 - deep inguinal 40, 622
 - external iliac 40, 82, 233, 266, 622
 - positive axillary 526
 - positive regional 215, 342
 - superficial inguinal 39–40, 74, 266, 621
- lymphadenectomy 54, 58, 64, 74, 222–23, 287–91, 293–96, 300, 302, 321, 326, 331, 333, 452, 615
- laparoscopic 228–29, 779–80
- lymphatic drainage 39–40, 82, 199, 266, 341, 504–5, 621–22, 759
- lymphocytes 647, 697–98, 708
- lymphoedema 54–55, 65, 67, 227, 525
- magnetic resonance imaging (MRI) 50, 56, 210, 218, 229, 248, 281, 302, 513–16, 521, 540, 572, 574–81, 583–84, 779–80
- mammary Paget's disease (MPD) 518
- mastectomy 517–18, 524–26
- melanoma 56, 70–71, 695, 697–98, 705, 708

- malignant 43, 48, 69–71, 446, 707
- Merkel-cell tumours 68
- metabolites, active 667, 669–70, 691
- metastases, brain 422, 453, 489–90, 494–95, 638
- methotrexate 442, 451, 453, 492, 527, 544, 546, 664, 666, 669, 682, 688, 722, 726
- micrometastases 57, 59, 234, 281
- mitomycin 65, 672–73, 682, 724, 726
- mitotic index 322, 325, 327, 379–80, 593, 595
- MLC *see* multi-leaf collimator
- MPD *see* mammary Paget's disease
- MRI *see* magnetic resonance
 - imaging
- mucinous cystadenocarcinoma 368
- mucinous tumour 366, 368, 373
 - high-grade 378
- mucositis 409, 494, 669, 672, 691–92, 722, 735, 753
- multi-leaf collimator (MLC) 650, 656
- myoinvasion 269, 275, 281, 289, 291, 293–94, 299, 302
- myometrial invasion 270, 281, 283, 298, 300–1, 319, 579–80, 716
 - deep 287, 295, 299, 303, 328, 330
- myometrium 264–65, 278, 282, 317–18, 325, 328, 574–75, 580
- neck cancers 143, 149, 201, 415, 566, 639, 690
- necrosis 231, 320, 329, 438, 488, 646, 691, 727, 731, 736–37
- neoplasia 274
- nephrotoxicity 690–91, 724–25
- neuroendocrine tumours 68, 246, 371
 - small cell 216, 228, 246
- neurotoxicity 300, 391, 399, 409, 690–91, 724
- neutropenia 395, 406, 408–9, 413, 694, 725–26
- nodal metastasis 51, 53, 67, 71, 208, 213, 217–19, 250, 295, 471, 488, 525, 615
- non-squamous cell carcinoma of cervix, treatment 245
- nucleotides 13–14, 20, 360
- nutritional therapies 600, 745
- obesity 2, 4, 49, 266–68, 270–71, 316, 354, 460, 509
- OCPs *see* oral contraceptive pills
- oesophagus 4–6, 565
- oestrogen 29, 191, 268, 270, 276–77, 321, 325, 422, 458, 460, 466–68, 507, 519–20, 712–13, 717
- oestrogen receptor 414, 511, 711–12
- omentectomy 281, 287, 290, 301–2, 330, 376, 378, 387, 452, 471, 550
- omentum 249, 287, 372, 387, 400, 410, 624–25, 731
- oncogenes 16, 21–26, 28, 31, 140, 201, 203, 344, 381
- oncoproteins 118, 131, 139–40, 203–4
- oral contraceptive 135, 205, 272, 277, 316, 350, 352–54, 357, 423, 476, 485, 508, 717
- oral contraceptive pills (OCPs)
 - 205, 272, 277, 350, 352–54, 357–58, 460, 476, 485, 508, 717–18
- organogenesis 543–44, 692

- ototoxicity 685, 691, 724
 ovarian cancer 9, 27–31, 343–45,
 350, 352–59, 361–65,
 371–77, 379–81, 383–94,
 401–2, 419–25, 507–8,
 549–50, 557–64, 696–99
 advanced epithelial 373, 376,
 384–85, 387, 401, 674
 cumulative risk of developing 9,
 352
 diagnosis 401
 early 361, 384, 778
 early-stage 372, 382
 endometrioid 28
 high-risk early-stage 420
 lifetime risk of 28, 353, 356
 mortality 364, 559
 platinum-resistant 390, 403, 407,
 409, 412
 platinum-resistant epithelial
 407–9
 platinum-sensitive 405, 411, 416
 platinum-sensitive recurrent
 407, 415
 prevention of 357, 359
 radiation therapy 419
 recurrent 391, 393, 402–4,
 410–11, 415–16, 418, 423,
 716
 recurrent epithelial 452
 refractory 403, 408–9
 refractory epithelial 407, 411
 screening 361, 363
 surgery 374
 ovarian cancer cell 372, 376, 425,
 564
 ovarian cancer cell proliferation
 376, 564
 ovarian carcinogenesis 356–57
 ovarian carcinoma 25, 28, 269,
 290, 343–46, 355, 372, 383,
 402, 412, 422, 449, 581–83,
 595, 716–17
 ovarian carcinoma antigen 375,
 563
 ovarian choriocarcinomas 449
 ovarian fibroma 464–65
 ovarian germ cell tumours,
 malignant 438, 440, 447,
 450–51, 454
 ovarian masses 375, 549
 ovarian neoplasms 365–68,
 463–64, 469
 ovarian tumour 269, 422, 438,
 462, 466, 716
 borderline 380–82
 malignant 458, 581
 paclitaxel 239–40, 247, 298–301,
 323, 332–33, 345, 390–91,
 394–96, 405–7, 409, 495,
 529, 671, 689–90, 723–24
 Paget's disease 42–44, 48
 pancreatic cancer 408, 562, 694
 papillomavirus infection, human
 45, 141
 para-aortic lymphadenectomy
 217, 287, 290–91, 301, 330,
 376, 411, 776
 paracentesis 379, 766–68
 parenteral nutrition 600, 742, 745
 patients
 chemotherapy-naïve 453
 cytoreduced 378
 elderly 595
 high-risk 92, 250, 326, 460, 515,
 550, 603
 ill 752–54
 low-risk 173, 218, 492
 malnourished 600, 742, 744,
 747–48, 751–53
 non-cancer 590
 non-pregnant 546, 550
 platinum-sensitive 403–6, 413
 postoperative management of
 298, 395
 pregnant 578
 radiotherapy-naïve 303

- uncooperative 748, 760
- untreated 678
- well-nourished 742–43
- pegylated liposomal doxorubicin (PLD) 395, 406, 408–9, 412–13, 669
- pelvic irradiation 84, 293, 297, 299, 316, 332, 346, 442, 647
- external 230, 232–33, 296
- pelvic lymph node metastasis 54, 208, 287, 296
- pelvic lymph nodes 39–40, 51–52, 208, 213, 371, 615–16, 621–22, 643, 776
- pelvic lymphadenectomy 53, 90, 93, 216–18, 222, 226–28, 230, 250, 289, 291, 547–48, 612
- routine 54, 288
- pelvic mass 317, 341, 374, 440, 560–61
- pelvic nerve 617–18, 633
- pelvic node metastasis 229, 287, 290–91
- pelvic pain 89, 208, 234, 317, 320, 326, 341
- pelvic radiation 293, 297–98, 547, 644
- pelvic radiotherapy 60, 86, 543
- pelvic spaces 611, 633
- pelvic splanchnic nerve 226, 617–18
- pelvic surgery 597–98, 628
- pelvic wall 82, 89, 211–12, 249
- pelvis 40, 49–50, 60, 91–93, 230, 233, 293–95, 318–19, 342, 376–77, 420–21, 582–83, 613–15, 622, 653
- false 610
- true 89, 211–12, 377, 421, 610–11, 614
- penile cancer 56, 135
- perineal body 36, 38–39, 49, 618, 621
- perineum 36, 51, 617, 621
- peritoneal cancers 359
- primary 392, 778
- peritoneal cavity 278, 320, 326, 340, 376, 396, 398–99, 420, 464, 623, 626, 765–67
- peritoneal metastasis 342, 377
- peritoneum 198, 264, 340, 350, 362, 368, 371, 381, 386, 396, 411, 611, 614–15, 623, 767
- Peutz-Jeghers syndrome 356, 468, 471–72
- PFS *see* progression-free survival
- placenta 272, 277, 476, 478–79, 483, 543, 545, 551
- placental site trophoblastic tumour (PSTT) 477–78, 487–89, 495–96
- placental site trophoblastic tumour, treatment 495
- platinum-sensitive patients, treatment 403, 405
- PLD *see* pegylated liposomal doxorubicin
- pleural effusion 377, 400, 595, 758–59, 761, 764
- pleurocentesis 758–61
- positive predictive value (PPV) 98, 104, 109, 113, 115, 117–19, 121, 278, 361–65, 556–57, 559–60, 563, 577, 583
- post-cryotherapy care 187
- post-menopausal women 41, 47, 67–68, 110, 175, 216, 225, 277–78, 328, 353–54, 361–63, 507–8, 527–28, 532, 557
- PPV *see* positive predictive value
- pre-cancerous state 696
- pre-malignant lesions of
 - endometrium 272–73, 275, 283, 285
 - treatment 283, 285
- precancerous lesions 99, 145, 162
- screening 99

- pregnancy 158, 161, 188, 190–91, 228–29, 265–66, 272, 277, 352, 362, 438, 476–77, 487, 539–52, 562–63
 antecedent 496
 normal 483, 490, 549, 551
 progestogen therapy 272, 299, 303–4, 714
 progestogens 277, 284, 304, 326, 423, 714–16
 prognostic nutritional index 744
 progression-free survival (PFS) 235, 237–41, 297, 299, 304, 321–22, 373, 386, 391, 393–95, 399, 401–2, 405–6, 411–12, 417–18
 prophylaxis 598
 prostate cancers 698, 706
 proteins 13–15, 18, 20–23, 25, 31–32, 130–31, 139–40, 142, 164, 203–4, 374, 418–19, 528–29, 561, 699
 immunosuppressive acidic 567
 tumour suppressor 203–4
 proteomics 31–32, 277, 365, 556
 proto-oncogenes 21–25
 mutated 21–23
 PSTT *see* placental site trophoblastic tumour
 pulmonary toxicity 723
- radiation, ionizing 354, 575, 638, 640
 radiation dose 542, 641, 645, 647–49, 651, 728
 absorbed fetal 543
 radiation injuries 210, 645, 727
 radiation oncologist 640, 648
 radiation therapy 63, 88, 90–91, 230, 234, 238, 246, 419, 421–22, 543, 638, 640–41, 646–49, 727, 753
 abdomino-pelvic 419–20
 electron 652
 image-guided 651
 modulated 650–51
 side effects of 727
 radical hysterectomy 93, 216–17, 219, 221–27, 229, 237–38, 245–46, 545, 547–48, 612, 618, 730, 732–33, 768, 779
 radical trachelectomy 216, 228–30, 548, 780–81
 radiotherapy 59–60, 71, 88–90, 93–94, 215, 220–22, 230–31, 233, 242–43, 292–93, 296–304, 524–27, 637–42, 644–46, 650–56
 adjuvant 220–21
 beam 231, 639
 conformal 650
 effectiveness of 233, 242
 neoadjuvant 292, 643
 palliative 233, 643
 primary 59–60, 217–19, 243, 292
 radical 243, 643
 recurrence-free survival 296, 299, 384, 496, 565, 776
 recurrent respiratory papillomatosis (RRP) 137, 141, 143
 residual tumour 237, 345, 378, 385, 395, 400, 411, 420–21, 566, 648
 resistant tumour 421, 698
 risk of ovarian malignancy algorithm (ROMA) 375
 robotic surgery 225, 775–76, 778, 780–82, 784
 ROMA *see* risk of ovarian malignancy algorithm
 RRP *see* recurrent respiratory papillomatosis
- SAAG *see* serum-ascites albumin gradient

- salpingo-oophorectomy, bilateral 321, 328, 330–31
- sarcomas 48, 71, 206, 213, 317, 328–29, 332, 367, 446, 652, 707
- SCC *see* squamous cell carcinoma
- sclerosing stromal tumour (SST) 459, 465
- SCST *see* sex cord-stromal tumour
- sebaceous glands 37–38, 619, 621, 646
- sentinel node biopsy 56–57, 71, 210, 216
- sentinel node mapping 54, 57–58, 229, 541
- serous borderline tumour 366, 368
- serous carcinoma, uterine papillary 300–1
- serous cystadenocarcinoma 366, 557
- serous tumour 365–66, 373, 375, 562
- Sertoli cell tumour 458–59, 466
- Sertoli–Leydig cell tumours 459, 466–67, 470, 472
- Sertoli-stromal cell tumours 459, 465–67
- serum-ascites albumin gradient (SAAG) 766
- serum biomarkers 560–62
- serum testosterone 469–70
- serum tumour markers 440, 563, 566–67
- sex cord-stromal tumour (SCST) 457–60, 462, 464, 466, 468, 470–72, 563
- sexually transmitted disease (STD) 133–34, 137, 204
- signet-ring stromal tumour 465
- Skene's glands 37–38, 618–20
- skin cancer 652, 695
- skin lesions 132–33
- smooth muscle tumours 320
- solid tumours 20, 304, 384, 412, 420, 446, 463, 466, 677, 700
- squamous cell carcinoma (SCC) 29, 41–42, 48, 50, 53–57, 59, 65, 67, 69, 204, 206, 244–45, 269, 446, 565–66
- squamous cell carcinoma antigen 446, 565–66
- squamous intraepithelial lesions high-grade 102, 108, 137, 173 low-grade 112, 137, 173
- SST *see* sclerosing stromal tumour
- stem cells 17
- stereotactic radiosurgery 642, 651
- steroid cell tumours 458–59, 469–70
- stomach 3, 5–6, 603, 623–25, 695, 697, 743, 746, 748
- stromal sarcoma, low-grade endometrial 715, 717
- suprapubic catheter 768–70
- sutures 626, 628, 632, 635, 763
- systematic pelvic lymphadenectomy 288
- tamoxifen 271, 273, 277, 280, 304, 316, 325, 403, 414, 423, 510, 527–28, 531–32, 712–13, 715–16
- taxanes 246, 390, 396, 412, 527, 530, 664, 670–71, 685, 722, 724
- teratoma, mature 340, 366, 440, 444–45, 448
- term pregnancies 488, 507, 540, 546
- testicular cancer 451–53, 660 management of 451, 453
- theeca lutein cysts 480–81, 486
- thecoma 367, 459, 463–64, 471
- thromboembolism 590, 596–98, 605, 693
- thromboprophylaxis 66, 596–97

- TNF *see* tumour necrosis factor
 total laparoscopic radical hysterectomy 238
 total parenteral nutrition (TPN) 600, 733, 746–47, 751–54, 772
TPN *see* total parenteral nutrition
 trachelectomy 182–83, 216, 228–30
 transitional cell tumour 369
 transvaginal ultrasound 277–78, 280, 341, 359, 361, 572, 578
 trastuzumab 25, 242, 305, 416, 520, 529–30, 682, 700–1
 trophoblastic disease, persistent 486, 491
 tumour
 advanced 60, 238
 aneuploid 379
 bulky 215, 218, 386, 411
 differentiation of 269, 713
 high-grade 324, 329, 356
 inoperable 71, 652
 low-grade 94
 malignant ovarian germ-cell 450
 metastatic 343, 367, 662–63
 microinvasive 381
 mixed mullerian 318, 327–28
 oestrogen-producing 270, 458, 464
 platinum-resistant 408–9
 polyvesicular vitelline 439, 444
 receptor-positive 303, 520
 unresectable 379, 530
 tumour cell necrosis 320, 325, 328
 tumour cells 20, 31, 234, 242, 370, 425, 585, 641, 648, 660, 663–64, 679, 696, 704, 706–7
 active 585
 clonogenic 647
 drug-resistant 666
 tumour debulking 321, 330, 550
 tumour implantation 547, 647
 tumour-limiting factors 705–6
 tumour markers 31, 210, 280, 362–63, 401, 441, 448, 462–63, 468, 471, 522, 549, 556, 564, 567
 tumour microenvironment 357, 704, 707
 tumour necrosis factor (TNF) 27, 696, 698, 708, 750
 tumour recurrence 218, 572, 576, 578, 730
 tumour regression 698, 705
 tumour resistance 698
 tumour suppressor genes 16, 20–22, 24–26, 28–29, 31, 140, 356, 381
 mutations of 21, 29

 UPSC *see* uterine papillary serous carcinoma
 ureteric stricture 227, 727, 730
 uterine artery 82, 199, 233, 265, 612–14
 uterine cancers 8–9, 316, 321, 328, 340, 567, 631, 647, 776
 comprehensive surgical staging of 776
 uterine carcinosarcoma 328–33
 uterine leiomyosarcoma 320–21, 323–25, 331, 333
 uterine papillary serous carcinoma (UPSC) 268, 300–2
 uterine sarcomas 273, 315–20, 322, 324–28, 330–32, 669, 717, 732
 undifferentiated 316, 324, 327

 vagina, adenocarcinoma of 85
 vaginal adenosis 85
 vaginal brachytherapy 301
 vaginal cancer 9, 83–84, 89–92, 94, 148

- advanced 92
- aetiology 84
- management 90
- primary 83–84
- radiation therapy 91
- vaginal carcinoma 89, 136
- vaginal discharge 49, 85, 87, 89, 328, 341
- vaginal hysterectomy, radical 779
- vaginal intraepithelial neoplasm 86–87, 156
 - treatment 87
- vaginal melanoma 84, 92–93
- vaginal metastases 489–90
- vaginal orifice 37–38, 619–20
- vaginal resection 224
- vaginal stenosis 88, 215, 731
- vaginectomy, partial 93–94
- vascular endothelial growth factor (VEGF) 26, 304, 414–15, 418, 567, 700–1
- VEGF *see* vascular endothelial growth factor
- venous thromboembolism 66, 158, 598–99
- vinblastine 460, 664, 667, 670, 682
- vinca alkaloids 544, 665, 670, 672–73, 724, 726
- vincristine 94, 424, 442, 451–53, 460, 494–95, 664, 667, 670, 682, 726
- vinorelbine 240–41, 670, 682
- viruses 18, 24, 133, 138, 165, 201–2, 725
- vomiting 409, 600–1, 646, 672, 681, 683, 736, 748, 784
- vulva 29, 35–44, 46, 48–58, 60–72, 74, 83, 87, 134, 143, 173–75, 189, 617–22
 - anatomy 36–37, 39, 618–19, 621
- vulva intraepithelial neoplasm 44–47
 - treatment 45
- vulva melanoma 70–71
- vulvar cancer 9, 29, 48–53, 56–57, 60, 62, 64, 66–69, 148, 551, 583–84
 - advanced 63
 - early 59, 61, 584
 - early-stage 58–59
 - metastatic 63
 - non-HPV-related 48–49
 - operable 57
 - ultrasound scan 583
- vulvar carcinoma 29, 50, 60, 62, 67
- vulvar intraepithelial neoplasia 164
- vulvar sarcoma 71
- vulvar tumour 58

- WAI *see* whole abdominal irradiation
- whole abdominal irradiation (WAI) 331, 346
- women
 - cancer-free 510
 - disease-free 121
 - lactating 158, 161
 - non-pregnant 190, 546–47, 550
 - nulliparous 205, 352, 357
 - obese 270–71, 277
 - older 41, 49, 109, 119, 189, 320, 371, 485, 518
 - pre-menopausal 215, 270, 278, 285, 372, 528
 - pregnant 158, 161, 190–91, 373, 541, 545
 - young 84, 90, 155, 202, 328, 440, 476, 507

- yeast cells 15, 146–47
- yolk sac tumour 84, 439, 443–44, 449–50, 468